Cargando…
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial
BACKGROUND: Goals of management in patients with heart failure and reduced ejection fraction include reducing death and hospitalizations, and improving health status (symptoms, physical function, and quality of life). In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Fa...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964869/ https://www.ncbi.nlm.nih.gov/pubmed/31736335 http://dx.doi.org/10.1161/CIRCULATIONAHA.119.044138 |
_version_ | 1783488538170359808 |
---|---|
author | Kosiborod, Mikhail N. Jhund, Pardeep S. Docherty, Kieran F. Diez, Mirta Petrie, Mark C. Verma, Subodh Nicolau, Jose C. Merkely, Béla Kitakaze, Masafumi DeMets, David L. Inzucchi, Silvio E. Køber, Lars Martinez, Felipe A. Ponikowski, Piotr Sabatine, Marc S. Solomon, Scott D. Bengtsson, Olof Lindholm, Daniel Niklasson, Anna Sjöstrand, Mikaela Langkilde, Anna Maria McMurray, John J.V. |
author_facet | Kosiborod, Mikhail N. Jhund, Pardeep S. Docherty, Kieran F. Diez, Mirta Petrie, Mark C. Verma, Subodh Nicolau, Jose C. Merkely, Béla Kitakaze, Masafumi DeMets, David L. Inzucchi, Silvio E. Køber, Lars Martinez, Felipe A. Ponikowski, Piotr Sabatine, Marc S. Solomon, Scott D. Bengtsson, Olof Lindholm, Daniel Niklasson, Anna Sjöstrand, Mikaela Langkilde, Anna Maria McMurray, John J.V. |
author_sort | Kosiborod, Mikhail N. |
collection | PubMed |
description | BACKGROUND: Goals of management in patients with heart failure and reduced ejection fraction include reducing death and hospitalizations, and improving health status (symptoms, physical function, and quality of life). In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure), sodium–glucose cotransporter-2 inhibitor, dapagliflozin, reduced death and hospitalizations, and improved symptoms in patients with heart failure and reduced ejection fraction. In this analysis, we examine the effects of dapagliflozin on a broad range of health status outcomes, using the Kansas City Cardiomyopathy Questionnaire (KCCQ). METHODS: KCCQ was evaluated at randomization, 4 and 8 months. Patients were divided by baseline KCCQ total symptom score (TSS); Cox proportional hazards models examined the effects of dapagliflozin on clinical events across these subgroups. We also evaluated the effects of dapagliflozin on KCCQ-TSS, clinical summary score, and overall summary score. Responder analyses were performed to compare proportions of dapagliflozin versus placebo-treated patients with clinically meaningful changes in KCCQ at 8 months. RESULTS: A total of 4443 patients had available KCCQ at baseline (median KCCQ-TSS, 77.1 [interquartile range, 58.3–91.7]). The effects of dapagliflozin vs placebo on reducing cardiovascular death or worsening heart failure were consistent across the range of KCCQ-TSS (lowest to highest tertile: hazard ratio, 0.70 [95% CI, 0.57–0.86]; hazard ratio, 0.77 [95% CI, 0.61–0.98]; hazard ratio, 0.62 [95% CI, 0.46–0.83]; P for heterogeneity=0.52). Patients treated with dapagliflozin had greater improvement in mean KCCQ-TSS, clinical summary score, and overall summary score at 8 months (2.8, 2.5 and 2.3 points higher versus placebo; P<0.0001 for all). Fewer patients treated with dapagliflozin had a deterioration in KCCQ-TSS (odds ratio, 0.84 [95% CI, 0.78–0.90]; P<0.0001); and more patients had at least small, moderate, and large improvements (odds ratio, 1.15 [95% CI, 1.08–1.23]; odds ratio, 1.15 [95% CI, 1.08–1.22]; odds ratio, 1.14 [95% CI, 1.07–1.22]; number needed to treat=14, 15, and 18, respectively; P<0.0001 for all; results consistent for KCCQ clinical summary score and overall summary score). CONCLUSIONS: Dapagliflozin reduced cardiovascular death and worsening heart failure across the range of baseline KCCQ, and improved symptoms, physical function, and quality of life in patients with heart failure and reduced ejection fraction. Furthermore, dapagliflozin increased the proportion of patients experiencing at least small, moderate, and large improvements in health status; these effects were clinically important. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03036124. |
format | Online Article Text |
id | pubmed-6964869 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-69648692020-02-03 Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial Kosiborod, Mikhail N. Jhund, Pardeep S. Docherty, Kieran F. Diez, Mirta Petrie, Mark C. Verma, Subodh Nicolau, Jose C. Merkely, Béla Kitakaze, Masafumi DeMets, David L. Inzucchi, Silvio E. Køber, Lars Martinez, Felipe A. Ponikowski, Piotr Sabatine, Marc S. Solomon, Scott D. Bengtsson, Olof Lindholm, Daniel Niklasson, Anna Sjöstrand, Mikaela Langkilde, Anna Maria McMurray, John J.V. Circulation Original Research Articles BACKGROUND: Goals of management in patients with heart failure and reduced ejection fraction include reducing death and hospitalizations, and improving health status (symptoms, physical function, and quality of life). In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure), sodium–glucose cotransporter-2 inhibitor, dapagliflozin, reduced death and hospitalizations, and improved symptoms in patients with heart failure and reduced ejection fraction. In this analysis, we examine the effects of dapagliflozin on a broad range of health status outcomes, using the Kansas City Cardiomyopathy Questionnaire (KCCQ). METHODS: KCCQ was evaluated at randomization, 4 and 8 months. Patients were divided by baseline KCCQ total symptom score (TSS); Cox proportional hazards models examined the effects of dapagliflozin on clinical events across these subgroups. We also evaluated the effects of dapagliflozin on KCCQ-TSS, clinical summary score, and overall summary score. Responder analyses were performed to compare proportions of dapagliflozin versus placebo-treated patients with clinically meaningful changes in KCCQ at 8 months. RESULTS: A total of 4443 patients had available KCCQ at baseline (median KCCQ-TSS, 77.1 [interquartile range, 58.3–91.7]). The effects of dapagliflozin vs placebo on reducing cardiovascular death or worsening heart failure were consistent across the range of KCCQ-TSS (lowest to highest tertile: hazard ratio, 0.70 [95% CI, 0.57–0.86]; hazard ratio, 0.77 [95% CI, 0.61–0.98]; hazard ratio, 0.62 [95% CI, 0.46–0.83]; P for heterogeneity=0.52). Patients treated with dapagliflozin had greater improvement in mean KCCQ-TSS, clinical summary score, and overall summary score at 8 months (2.8, 2.5 and 2.3 points higher versus placebo; P<0.0001 for all). Fewer patients treated with dapagliflozin had a deterioration in KCCQ-TSS (odds ratio, 0.84 [95% CI, 0.78–0.90]; P<0.0001); and more patients had at least small, moderate, and large improvements (odds ratio, 1.15 [95% CI, 1.08–1.23]; odds ratio, 1.15 [95% CI, 1.08–1.22]; odds ratio, 1.14 [95% CI, 1.07–1.22]; number needed to treat=14, 15, and 18, respectively; P<0.0001 for all; results consistent for KCCQ clinical summary score and overall summary score). CONCLUSIONS: Dapagliflozin reduced cardiovascular death and worsening heart failure across the range of baseline KCCQ, and improved symptoms, physical function, and quality of life in patients with heart failure and reduced ejection fraction. Furthermore, dapagliflozin increased the proportion of patients experiencing at least small, moderate, and large improvements in health status; these effects were clinically important. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03036124. Lippincott Williams & Wilkins 2020-01-14 2019-11-17 /pmc/articles/PMC6964869/ /pubmed/31736335 http://dx.doi.org/10.1161/CIRCULATIONAHA.119.044138 Text en © 2019 The Authors. Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited. |
spellingShingle | Original Research Articles Kosiborod, Mikhail N. Jhund, Pardeep S. Docherty, Kieran F. Diez, Mirta Petrie, Mark C. Verma, Subodh Nicolau, Jose C. Merkely, Béla Kitakaze, Masafumi DeMets, David L. Inzucchi, Silvio E. Køber, Lars Martinez, Felipe A. Ponikowski, Piotr Sabatine, Marc S. Solomon, Scott D. Bengtsson, Olof Lindholm, Daniel Niklasson, Anna Sjöstrand, Mikaela Langkilde, Anna Maria McMurray, John J.V. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial |
title | Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial |
title_full | Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial |
title_fullStr | Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial |
title_full_unstemmed | Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial |
title_short | Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial |
title_sort | effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the dapa-hf trial |
topic | Original Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964869/ https://www.ncbi.nlm.nih.gov/pubmed/31736335 http://dx.doi.org/10.1161/CIRCULATIONAHA.119.044138 |
work_keys_str_mv | AT kosiborodmikhailn effectsofdapagliflozinonsymptomsfunctionandqualityoflifeinpatientswithheartfailureandreducedejectionfractionresultsfromthedapahftrial AT jhundpardeeps effectsofdapagliflozinonsymptomsfunctionandqualityoflifeinpatientswithheartfailureandreducedejectionfractionresultsfromthedapahftrial AT dochertykieranf effectsofdapagliflozinonsymptomsfunctionandqualityoflifeinpatientswithheartfailureandreducedejectionfractionresultsfromthedapahftrial AT diezmirta effectsofdapagliflozinonsymptomsfunctionandqualityoflifeinpatientswithheartfailureandreducedejectionfractionresultsfromthedapahftrial AT petriemarkc effectsofdapagliflozinonsymptomsfunctionandqualityoflifeinpatientswithheartfailureandreducedejectionfractionresultsfromthedapahftrial AT vermasubodh effectsofdapagliflozinonsymptomsfunctionandqualityoflifeinpatientswithheartfailureandreducedejectionfractionresultsfromthedapahftrial AT nicolaujosec effectsofdapagliflozinonsymptomsfunctionandqualityoflifeinpatientswithheartfailureandreducedejectionfractionresultsfromthedapahftrial AT merkelybela effectsofdapagliflozinonsymptomsfunctionandqualityoflifeinpatientswithheartfailureandreducedejectionfractionresultsfromthedapahftrial AT kitakazemasafumi effectsofdapagliflozinonsymptomsfunctionandqualityoflifeinpatientswithheartfailureandreducedejectionfractionresultsfromthedapahftrial AT demetsdavidl effectsofdapagliflozinonsymptomsfunctionandqualityoflifeinpatientswithheartfailureandreducedejectionfractionresultsfromthedapahftrial AT inzucchisilvioe effectsofdapagliflozinonsymptomsfunctionandqualityoflifeinpatientswithheartfailureandreducedejectionfractionresultsfromthedapahftrial AT køberlars effectsofdapagliflozinonsymptomsfunctionandqualityoflifeinpatientswithheartfailureandreducedejectionfractionresultsfromthedapahftrial AT martinezfelipea effectsofdapagliflozinonsymptomsfunctionandqualityoflifeinpatientswithheartfailureandreducedejectionfractionresultsfromthedapahftrial AT ponikowskipiotr effectsofdapagliflozinonsymptomsfunctionandqualityoflifeinpatientswithheartfailureandreducedejectionfractionresultsfromthedapahftrial AT sabatinemarcs effectsofdapagliflozinonsymptomsfunctionandqualityoflifeinpatientswithheartfailureandreducedejectionfractionresultsfromthedapahftrial AT solomonscottd effectsofdapagliflozinonsymptomsfunctionandqualityoflifeinpatientswithheartfailureandreducedejectionfractionresultsfromthedapahftrial AT bengtssonolof effectsofdapagliflozinonsymptomsfunctionandqualityoflifeinpatientswithheartfailureandreducedejectionfractionresultsfromthedapahftrial AT lindholmdaniel effectsofdapagliflozinonsymptomsfunctionandqualityoflifeinpatientswithheartfailureandreducedejectionfractionresultsfromthedapahftrial AT niklassonanna effectsofdapagliflozinonsymptomsfunctionandqualityoflifeinpatientswithheartfailureandreducedejectionfractionresultsfromthedapahftrial AT sjostrandmikaela effectsofdapagliflozinonsymptomsfunctionandqualityoflifeinpatientswithheartfailureandreducedejectionfractionresultsfromthedapahftrial AT langkildeannamaria effectsofdapagliflozinonsymptomsfunctionandqualityoflifeinpatientswithheartfailureandreducedejectionfractionresultsfromthedapahftrial AT mcmurrayjohnjv effectsofdapagliflozinonsymptomsfunctionandqualityoflifeinpatientswithheartfailureandreducedejectionfractionresultsfromthedapahftrial |